Across TCGA pan-cancer cohorts, NYAP1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NYAP1 data layer compared with 26 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NYAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NYAP1 expression acts as an unfavorable survival marker.
LSCC and CCRCC are the cancer types where NYAP1 mass-spec protein most reproducibly stratifies survival.